Potential impact of nirsevimab and bivalent maternal vaccine against RSV bronchiolitis in infants: A population-based modelling study

• Auteurs principaux: Mónica López-Lacort (Auteur), Ana Corberán-Vallet (Auteur), Francisco J. Santonja (Auteur), Cintia Muñoz-Quiles (Auteur), Javier Díez-Domingo (Auteur), Alejandro Orrico-Sánchez (Auteur)
• Format: Livre
• Publié: Elsevier, 2024-08-01T00:00:00Z.
• Sujets: article
• Accès en ligne: Connect to this object online.

Background: A new monoclonal antibody (nirsevimab; Beyfortus®) and a bivalent prefusion RSV vaccine (Abrysvo®) for maternal immunization have been approved recently. This is a modelling study to estimate the potential impact of different immunization programs with these products on RSV-bronchiolitis...